Ligand receives US$ 6.5 mn from Roche for progression of RG7348 into phase-I trial in treatment of HCV infection

Ligand receives US$ 6.5 mn from Roche for progression of RG7348 into phase-I trial in treatment of HCV infection
Ligand Pharmaceuticals Incorporated announced that it earned a US$ 6.5 million payment from Roche as a result of Roche progressing RG7348 into a phase-I clinical trial for the treatment of hepatitis C viral (HCV) infection.

Read more on PharmaBiz